Press Releases Detail:
Avitar Invited to Present at Emerging Medical Technologies East Conference Tomorrow in Cambridge
September 05, 2001
CANTON, Mass., Sept. 5 /PRNewswire/ -- Avitar, Inc. (Amex: - news) today announced that it has been invited to make a presentation at IHS Health Group's Emerging Medical Technologies East (EMT) Conference & Exhibition on Thursday, Sept. 6, at 3:30 p.m. at the Hyatt Regency Hotel in Cambridge, MA.
Avitar will be one of approximately 40 companies presenting during the two-day conference to an audience of investment professionals and industry leaders. Following Avitar's presentation, the company will participate in a breakout session for smaller group and one-on-one discussions. On Thursday evening, there will be a reception/exhibition with a tabletop display of products and literature.
This is the 5th annual Emerging Medical Technology Conference, and the eighth year that EMT conferences have been held in both the U.S. and Europe, to enable companies to potentially discuss areas such as financing, corporate alliances, joint ventures and distribution agreements
``We look forward to presenting at the EMT East Conference this week, and to be among the cutting-edge medical technology companies that will be in attendance,'' said Peter P. Phildius, Avitar's Chairman and Chief Executive Officer. ``This conference is well-known for putting companies, as well as investors, together to discuss areas of mutual interest.''
Avitar, Inc. (Amex: - news) headquartered in Canton, Massachusetts, is a diagnostics company that develops, manufactures and markets innovative and proprietary medical devices in two major areas: the oral fluid drugs-of-abuse market and the disease & clinical testing market. Oral fluid diagnostics includes both the drugs-of-abuse testing market estimated to be worth $1.5 billion encompassing the corporate workplace and criminal justice markets. Avitar's products include ORALscreen(TM), the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, and HAIRscreen(TM), a laboratory-based hair test for detecting long-term drug abuse. In the $20 billion disease & clinical testing market, Avitar is currently developing products that will address the conditions of Lyme disease, influenza and diabetes, as well as pregnancy.
For more information, see Avitar's website at avitarinc.com.
This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission.
Ingoldsby Investor Relations